As of early 2026, Amgen Inc. (NASDAQ: AMGN) has successfully transitioned from a legacy biologics provider into a diversified powerhouse driven by three distinct growth engines: cardiometabolic innovation, rare disease expansion, and cardiovascular leadership. Following the landmark $27.8 billion acquisition of Horizon Therapeutics, Amgen has not only integrated a high-margin rare disease portfolio but has also leveraged its proprietary “BiTE” (Bispecific T-cell Engager) and antibody-peptide platforms to challenge incumbents in the obesity and dyslipidemia markets.
This report provides a deep-dive analysis into the clinical progression of MariTide, the financial performance of the Horizon-integrated rare disease assets, and the sustained trajectory of the cardiovascular franchise. With a 2026 revenue guidance range of $37.0 billion to $38.4 billion, Amgen is positioned to deliver superior shareholder value through volume-driven growth and a robust late-stage pipeline.
Table of Contents
1. MariTide: Redefining the Obesity and Type 2 Diabetes Paradigm
The most significant catalyst in Amgen’s current pipeline is MariTide (maridebart cafraglutide), a first-in-class bispecific antibody-peptide conjugate. Unlike traditional GLP-1 receptor agonists, MariTide’s mechanism is dual-action: it activates the GLP-1 receptor while simultaneously inhibiting the GIP (gastric inhibitory polypeptide) receptor.
A. Phase 3 Clinical Progress and 2026-2027 Milestones
Amgen has moved aggressively into the MARITIME Phase 3 program, which currently consists of six global clinical trials. These studies are designed to evaluate MariTide across diverse populations, including those with obesity, overweight with comorbidities, and Type 2 Diabetes (T2D).
- Current Status: As of Q1 2026, the MARITIME-1 and MARITIME-2 trials (focused on chronic weight management) are nearing primary completion.
- Expected Milestones: Top-line data for the pivotal 52-week and 72-week obesity trials are anticipated in late 2026. Amgen has also signaled the initiation of specific Phase 3 trials for T2D in early 2026, following robust Phase 2 data that showed up to 17% weight loss in diabetic patients.
- Clinical Differentiation: Phase 2 data presented at the American Diabetes Association (ADA) demonstrated that weight loss with MariTide had not reached a plateau at 52 weeks, suggesting that longer-term treatment could yield efficacy exceeding the ~20% mean weight loss observed in earlier readouts.
B. Commercial Implications of the Dosing Profile
The “Holy Grail” of obesity treatment is patient adherence, which is frequently compromised by the “weekly injection fatigue” associated with current leaders like Zepbound and Wegovy. MariTide’s unique pharmacokinetic profile allows for:
- Monthly Dosing (Q4W): The primary commercial target for induction and intensive weight loss.
- Quarterly Dosing (Q12W): A potential maintenance paradigm that could disrupt the market.
Patient and Payer Advantages:
- Reduced Healthcare Utilization: Fewer injections mean lower costs for administration and better compliance.
- Sustainability: Preliminary data suggests that MariTide may offer better weight maintenance after cessation or during less frequent dosing intervals compared to traditional GLP-1s, potentially solving the “rebound weight gain” problem.
- Tolerability: Amgen’s titration strategy in Phase 3 aims to mitigate the gastrointestinal (GI) side effects that have historically led to high discontinuation rates in the incretin class.
C. Competitive Positioning and Disruption Potential
The obesity market is projected to reach $170B+ by 2031. While Eli Lilly and Novo Nordisk hold a massive first-mover advantage, Amgen is positioning MariTide not as a “me-too” drug, but as a second-generation disruptor.
| Feature | Current Standards (Weekly) | MariTide (Monthly/Quarterly) |
| Mechanism | GLP-1 or GLP-1/GIP Agonism | GLP-1 Agonism + GIP Antagonism |
| Frequency | 52 injections/year | 4 to 12 injections/year |
| Weight Loss | ~15% to 22% (plateaued) | ~20%+ (no plateau at 52 weeks) |
| Market Segment | Mass market / Early adopters | High-adherence / Long-term maintenance |
2. Rare Disease Portfolio: The Horizon Synergy Realized
The acquisition of Horizon Therapeutics was a strategic bet on high-orphan, low-competition markets. In 2025, Amgen’s rare disease portfolio achieved $5.2 billion in sales, officially hitting the corporate goal of $5B+ ahead of schedule.
A. Sales Performance of Key Assets (FY 2025 Data)
- Tepezza (teprotumumab-trbw): As the first and only FDA-approved treatment for Thyroid Eye Disease (TED), Tepezza remains the flagship asset. While it faced some initial integration hurdles, 2025 sales reached $1.9 billion. Growth is now being driven by expanded use in “low-CAS” (lower activity) patients and international launches.
- Uplizna (inebilizumab-cdon): This is Amgen’s fastest-growing rare disease asset, with 2025 sales surging 73% to $655 million. The recent launch for IgG4-related disease (IgG4-RD) has significantly expanded its addressable market beyond Neuromyelitis Optica Spectrum Disorder (NMOSD).
- Tavneos (avacopan): Used for ANCA-associated vasculitis, Tavneos delivered $459 million in 2025, a 62% year-over-year increase. Its adoption is accelerating as physicians transition away from long-term steroid use in vasculitis patients.
B. Scaling and Global Strategy
Amgen is utilizing its massive global infrastructure—spanning over 100 countries—to scale these former Horizon assets:
- Ex-U.S. Expansion: Tepezza is planned for launches in Europe and Japan throughout 2026.
- Portfolio Synergy: Amgen is bundling rare disease diagnostics with its existing inflammation sales force, creating a more efficient go-to-market model for specialists.
- Lifecycle Management: New Phase 3 studies for Uplizna in Myasthenia Gravis (MG) and other autoimmune conditions are underway to ensure the “pipeline-in-a-product” strategy extends the revenue tail.
C. Revenue Target Progress
Amgen’s management has now set its sights on a $10B+ annual rare disease revenue target by 2030. The current $5.2B run rate provides a stable, high-margin foundation that offsets the biosimilar erosion of legacy products like Enbrel.
3. The Cardiovascular Super-Franchise: Repatha and Olpasiran
Amgen’s cardiovascular (CV) segment is currently the company’s most reliable engine for volume growth, led by the PCSK9 inhibitor Repatha and the high-potential siRNA candidate Olpasiran.
A. Repatha’s 30%+ Growth Trajectory
In 2025, Repatha (evolocumab) achieved record sales of $3.1 billion, representing a 36% year-over-year increase. This growth is notable because it is driven by volume rather than price increases.
- Primary Drivers: Expansion in the primary prevention market and the publication of the VESALIUS-CV data, which expanded Repatha’s clinical utility to a broader range of high-risk patients.
- Market Penetration: Amgen has successfully navigated payer hurdles, making Repatha the preferred PCSK9 inhibitor in many U.S. and European formularies.
- 2026 Outlook: Management expects Repatha to maintain double-digit volume growth throughout 2026, despite mid-single-digit price declines due to increased Medicare utilization.
B. Olpasiran and the Lp(a) Mechanism
While Repatha targets LDL cholesterol, Olpasiran is a small interfering RNA (siRNA) designed to lower Lipoprotein(a)—a genetically determined, highly atherogenic risk factor for which there are currently no approved targeted therapies.
- Clinical Mechanism: Olpasiran reduces the liver’s production of apolipoprotein(a), thereby lowering Lp(a) levels. In Phase 2, Olpasiran reduced Lp(a) by >90%.
- OCEAN(a) Phase 3 Trial: The pivotal cardiovascular outcomes trial (CVOT) is currently in progress with over 7,200 participants.
- Catalysts: Primary outcome data collection is estimated to conclude in late 2026 or early 2027. If successful, Olpasiran could become a multi-billion-dollar “blockbuster” asset, as approximately 20% of the global population has elevated Lp(a).
4. Financial Synthesis and Investor Thesis
Amgen’s financial health remains robust, characterized by strong free cash flow and a disciplined capital allocation strategy.
Financial Summary Table (Estimated FY 2025-2026)
| Metric | 2025 Actual (Approx.) | 2026 Guidance/Forecast |
| Total Revenue | $36.8 Billion | $37.0B – $38.4B |
| Non-GAAP EPS | $21.84 | $21.60 – $23.00 |
| Free Cash Flow | $8.1 Billion | ~$9.0 Billion |
| Dividend Yield | ~2.6% | ~2.8% (projected) |
Investment Conclusion
Amgen represents a unique “Growth at a Reasonable Price” (GARP) opportunity in the large-cap biotech space.
- Defense: The Rare Disease portfolio and the Cardiovascular franchise (Repatha) provide a high-floor revenue stream with limited patent risk in the near term.
- Offense: MariTide and Olpasiran represent massive optionality in the two largest markets in medicine: obesity and cardiovascular disease.
- Capital Return: With a commitment to retiring debt post-Horizon and a steady 6% dividend increase history, Amgen remains a core holding for both growth and income-oriented investors.
The primary risk remains the competitive landscape in obesity, where Lilly and Novo Nordisk are entrenched. However, Amgen’s differentiated dosing profile (monthly vs. weekly) and its superior clinical data in T2D patients suggest a significant “market-taker” potential.